Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Recruiting Phase 3 Interventional Study
Systemic Lupus Erythematosus
Ready to participate?

Review the details below, then apply to join this clinical trial.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, the risk of HCQ retinal toxicity escalates with continued use. Evaluation using sensitive standard of…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Age ≥ 60 years at time of enrollment * Normal OCT and VF assessment within 6 months of screening visit * Ability to tak…
Contacts

Mala Masson

(212) 263-0372

Mala.Masson@nyulangone.org

CONTACT